15 results on '"Mycophenolate Sodium"'
Search Results
2. Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in de Novo Renal Transplant Patients: 4 Years Follow-Up of the ZEUS Trial
3. Everolimus Treated Renal Transplant Patients Develop a More Robust CMV-Specific CD8 Response Compared to Cyclosporine or Mycophenolate Sodium Treated Patients
4. Limited Sampling Strategy to Determine the Degree of Exposure to Mycophenolic Acid after Enteric- Coated Mycophenolate Sodium in Renal Transplant Adult Patients
5. EVEROLIMUS(E) VS ENTERIC COATED MYCOPHENOLATE SODIUM (EC-MPS): PROTEOMIC AND PATHOLOGIC ASPECTS IN A 1-YEAR PROSPECTIVE RANDOMIZED STUDY
6. INITIALLY INTENSIFIED DOSING REGIMEN OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) OFFERS EARLY ADEQUATE MYCOPHENOLIC ACID (MPA) EXPOSURE IN DE NOVO RENAL TRANSPLANT RECIPIENTS
7. INITIAL INTENSIFIED DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) VERSUS STANDARD DOSING IMPROVES REJECTION PROPHYLAXIS IN DE NOVO RENAL TRANSPLANT RECIPIENTS
8. A PROSPECTIVE MULTICENTER OPEN-LABEL RANDOMIZED STUDY TO ASSESS EFFICACY AND SAFETY OF EVEROLIMUS WITH CICLOSPORINE-MICROEMULSION (CSA-ME) VERSUS EVEROLIMUS WITHOUT CALCINEURINE INHIBITOR WITH MYCOPHENOLATE SODIUM, IN MAINTENANCE ADULT KIDNEY TRANSPLANT PATIENTS: FOREVER STUDY
9. POPULATION PHARMACOKINETICS OF MYCOPHENOLIC ACID: A COMPARISON BETWEEN ENTERIC-COATED MYCOPHENOLATE SODIUM AND MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS
10. COMPARABLE PATIENT REPORTED OUTCOMES WITH INITIALLY INTENSIFIED DOSING VERSUS STANDARD DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN DE NOVO RENAL TRANSPLANT RECIPIENTS
11. MYCOPHENOLATE SODIUM DOSING IN COMBINATION WITH TACROLIMUS: PHARMACOKINETIC EVALUATION OF A NOVEL REGIMEN IN DE NOVO KINEY TRANSPLANT PATIENTS
12. IMPROVED RENAL FUNCTION OF AN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM REGIMEN AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: 2 YEARS FOLLOW-UP OF THE ZEUS TRIAL
13. INTENSIFIED DOSE OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) FOR 6 WEEKS, IN COMBINATION WITH ANTI-IL2R INDUCTION, CYCLOSPORINE MICRO-EMULSION (CSA-ME) WITH OR WITHOUT STEROIDS, IN ADULT DE NOVO LOW IMMUNOLOGICAL RISK KIDNEY TRANSPLANT RECIPIENTS: FINAL EFFICACY AND SAFETY RESULTS OF A PROSPECTIVE MULTICENTER RANDOMIZED OPEN-LABEL STUDY: DOMINOS STUDY
14. PHARMOCOKINETICS OF MYCOPHENOLATE MOFETIL AND ENTERIC-COATED MYCOPHENOLATE SODIUM IN CALCINEURININHIBITOR-FREE TREATED RENAL TRANSPLANTAT PATIENTS
15. AN INTENSIFIED DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM IN RENAL TRANSPLANT PATIENTS RESULTS IN IMPROVED EFFICACY WITHOUT COMPROMISING SAFETY: 1 YEAR FOLLOW-UP RESULTS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.